A open label Randomized Active Controlled Non inferiority Parallel Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Revefenacin 175 mcg In 3 ml Inhalation Solution Manufactured by BDR Pharmaceuticals International Pvt Ltd India Comparing With Tiotropium Bromide Inhalation Powder Manufactured by Lupin Limited Pithampur M P 454775 India In Patients Receiving Tiotropium Bromide Inhalation Powder for Chronic Obstructive Pulmonary Disease - NIL

开始日期2026-01-05

申办/合作机构

BDR Pharmaceuticals International Pvt Ltd.

NCT07133880

/ Recruiting临床4期IIT

Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer Versus Dry Powder Inhaler in Symptomatic Patients With Chronic Obstructive Pulmonary Disease

The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).
The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI.
The study aims to demonstrate the following:
1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer

开始日期2023-12-05

申办/合作机构

University of Tennessee

[+1]

CTRI/2022/09/045402

/ Completed临床3期

A Double-Blind, placebo-controlled study of nebulized revefenacin inhalation solution in Indian Subjects with moderate to very severe chronic obstructive pulmonary disease (COPD).

开始日期2022-09-13

申办/合作机构

Mylan Pharmaceuticals Pvt Ltd.

100 项与瑞维那新相关的临床结果

登录后查看更多信息

100 项与瑞维那新相关的转化医学

登录后查看更多信息

100 项与瑞维那新相关的专利（医药）

登录后查看更多信息

项与瑞维那新相关的文献（医药）

2025-09-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Development of a novel stability-indicating UHPLC method for revefenacin quality control and impurity identification using 2D-LC-HRMS

Article

作者: Xu, Nuo ; Xiao, Chaoqiang ; Guo, Wei ; Sun, Lu ; Zhou, Sunxin ; Zhang, Weifeng ; He, Shuwang ; Zhang, Tong

Revefenacin (Rev) inhalation solution is the only once-daily nebulized bronchodilator approved in the USA for chronic obstructive pulmonary disease treatment. Despite the critical role of quality control in pharmaceutical manufacturing, no established methods exist for Rev, and its degradation pathways remain unreported. This study performed forced degradation to generate impurity-containing samples, which were used to develop a novel ultrahigh-performance liquid chromatography (UHPLC) method. Qualitative analysis of 12 impurities was conducted using two-dimensional liquid chromatography-high-resolution mass spectrometry. Characteristic fragment ions and mass fragmentation processes were examined, leading to the identification and verification of four specific impurities using reference standards. Impurities A (C₂₂H₃₃N₃O₄), B (C₃₅H₄₂N₄O₅), and C (C₁₂H₁₁N) were identified definitively by comparison to reference materials, while DP-9 and DP-11 were tentatively identified based on MS studies. The remaining seven impurities were not identified due to concentrations below the identification threshold. The primary degradation pathways of Rev were oxidation and hydrolysis. The UHPLC method achieved baseline separation of the 12 degradation products (DPs), and its effectiveness was confirmed by assessing sample stability under the proposed chromatographic conditions. The results demonstrate that this method is suitable for Rev quality control. The novel stability-indicating UHPLC method developed for quantifying Rev DPs offers a reliable approach for quality assurance.

2025-08-08·Cureus Journal of Medical Science

Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report

Article

作者: Singh, Sumi ; Chowdhury, Shafayath ; Shen, Kevin ; Weissman, Brandon

Asthma is one of the most prevalent chronic respiratory illnesses, significantly impacting patients through shortness of breath and even death. Acute exacerbations are usually controlled with a short-acting beta agonist, such as an albuterol inhaler, as well as long-acting agents to prevent the occurrence of exacerbations and status asthmaticus. Status asthmaticus is an emergent episode of asthma that is refractory to standard treatment. This disease presents as tachycardia, tachypnea, and dyspnea. The forced expiratory volume measures the severity of asthma in one second and the serial peak expiratory flow rate. Proper treatment is vital for patient survival. This case report reviews the proper treatment of a patient in her mid-30s presenting to the emergency department due to an asthmatic attack refractory to albuterol. The patient went through a five-stage treatment plan. First, the patient was treated with inhaled beta-2 agonist (albuterol) and corticosteroids (prednisone, dexamethasone, and methylprednisolone). The patient did not improve with these treatments and was given the anticholinergic agent ipratropium bromide in an attempt to increase bronchodilation. Nebulized racemic epinephrine was then added to the patient to optimize maximum bronchodilation and vasoconstriction in an attempt to reduce airway edema and inflammation. To reduce ventilator peak airway pressures through sedation and paralytics, rocuronium and cisatracurium (Nimbex) were administered. Ketamine was added as a sedative and bronchodilator. Propofol and midazolam (Versed) were used to sedate the patient for mechanical ventilation. After the acute episode, maintenance therapy included inhaled corticosteroids (budesonide), a long-acting beta-2 agonist (arformoterol), a long-acting muscarinic antagonist (revefenacin), and montelukast (a leukotriene receptor antagonist). This case illustrates the importance of status asthmaticus treatment as a vital, stepwise process that focuses on bronchodilation, maintaining the airway, mechanical ventilation, sedation, and reducing inflammation and paralysis.

2025-08-01·JOURNAL OF SEPARATION SCIENCE

Quantification and Aerodynamic Particle Size Distribution of Revefenacin Aerosol With UHPLC‐MS/MS

Article

作者: Chi, Xiaoqing ; Hong, Yawen ; Luo, Wenjie ; Dou, Jing ; Yuan, Chenxing ; Ping, Li ; Li, Qixiu ; Zhu, Difeng ; Chen, Chao

ABSTRACT:

Aerosol inhalation therapy offers significant benefits in treating chronic obstructive pulmonary disease, including rapid onset of action and reduced systemic side effects. Revefenacin, a long‐acting bronchodilator, has demonstrated efficacy in improving lung function and alleviating chronic obstructive pulmonary disease symptoms through aerosol delivery. However, quantitative methods for determining the inhaled concentration of revefenacin aerosol remain limited. This study developed and validated a rapid, robust ultrahigh‐performance liquid chromatography‐tandem mass spectrometry (UHPLC‐MS/MS) method to quantify revefenacin aerosol concentration. The method, with an analysis time of 2 min, exhibited excellent specificity, precision, and a lower limit of quantification of 2 ng/mL. The aerosol extraction recovery averaged 98.5%. The method was successfully applied to assess aerosol concentration and aerodynamic particle size distribution under different sampling conditions. Results showed that after 15 min of nebulization, the average aerosol concentrations collected using syringe aspiration and impactor sampling methods were 0.98 and 0.95 mg/m 3 , respectively, demonstrating consistency between the techniques. Aerodynamic particle size distribution analysis revealed stable particle size distribution with atomization times of 5 and 15 min, yielding mass median aerodynamic diameters of 2.31 and 2.35 µm, fine particle fractions of 76.5% and 76.7%, and geometric standard deviations of 2.44 and 2.41, respectively. These findings indicate that the aerodynamic properties of revefenacin aerosol remain stable over prolonged nebulization. This study establishes a reliable analytical method for revefenacin aerosol quantification and provides valuable insights into its aerodynamic characteristics, supporting its further application in chronic obstructive pulmonary disease treatment.

168

项与瑞维那新相关的新闻（医药）

2026-06-04

·米内网

【瞩目】江苏药企拿下重磅首仿，抢攻超500亿市场

精彩内容日前，国家药监局官网显示，江苏长泰药业的酒石酸阿福特罗雾化吸入溶液以仿制3类报产获批，是该产品首仿和首家过评企业。2025年至今，江苏长泰药业有4款产品获批上市，1款产品报产在审。来源：米内网一键检索酒石酸阿福特罗吸入溶液是一种长效支气管扩张剂，用于治疗慢性阻塞性肺疾病（COPD），主要通过雾化吸入给药，帮助患者缓解呼吸困难。米内网数据显示，酒石酸阿福特罗吸入溶液目前仅有江苏长泰药业拥有生产批文，湖南华纳大药厂、正大天晴药业集团均以仿制3类报产在审。近年中国三大终端六大市场呼吸系统用药（化+生）销售情况（单位：万元）来源：米内网格局数据库呼吸系统用药（化+生）在2025年中国三大终端六大市场（统计范围见文末）超过500亿元销售规模。从亚类来看，阻塞性气管疾病用药（化+生）市场份额最大，占比超过40%；其次是咳嗽和感冒用药（化），占比超过30%。从剂型来看，气雾剂/喷雾剂与粉雾剂、片剂、注射剂是3大畅销剂型，合计市场份额占比超过70%。 2025年中国三大终端六大市场呼吸系统用药（化+生）TOP3剂型来源：米内网格局数据库 2025年至今，江苏长泰药业有4款产品获批上市，其中，酒石酸阿福特罗雾化吸入溶液是首仿和首家过评，氨磺必利口服溶液、草酸艾司西酞普兰口服溶液在2025年中国三大终端六大市场销售额分别是大涨265.34%、315.56%潜力品种。此外，公司的瑞维那新吸入溶液以仿制4类报产在审，有望拿下首仿。江苏长泰药业2025年至今获批上市产品来源：米内网中国申报进度（MED）数据库资料显示，江苏长泰药业专注于呼吸道、神经类和肿瘤新药的研发和产业化，现有雾化吸入制剂、复杂固体制剂、长效微球制剂、靶向脂质体制剂等高端制剂的研发及GMP生产平台，主要产品有奥氮平氟西汀胶囊、吸入用异丙托溴铵溶液、盐酸托莫西汀口服溶液等。资料来源：国家药监局官网、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2026-06-01

·创新药物递送

全球经口吸入和鼻腔给药领域 · 头条速览（2026年5月下）

国内资讯 Domestic News 1 温医大附属眼视光医院携手汇芯生物，开展干细胞外泌体治疗外伤性视神经损伤临床研究媒体：细胞与基因治疗领域 2026/5/29 温医大联合汇芯生物，启动“脐带源间充质干细胞外泌体鼻喷剂治疗外伤性视神经损伤临床研究”项目。该项目聚焦脐带源间充质干细胞外泌体鼻喷剂，采用鼻腔给药路径开展研究，重点关注外泌体跨鼻黏膜递送、吸收效率及制剂稳定性等关键问题。 2 青峰医药集团引进帕金森吸入新药Inbrija® 媒体：青峰医药集团 2026/5/27 青峰医药集团旗下科睿药业与德国 Merz Therapeutics 达成独家合作，引进 Inbrija®（左旋多巴吸入粉雾剂）。科睿获得中国大陆及港澳地区帕金森病 OFF 期治疗的独家开发与商业化权利。Merz负责全球供应与质量，并持有境外注册证书；科睿负责本地开发、注册申报及商业化，并承担临床开发资金。 3 长风药业COPD领域新产品噻托溴铵吸入粉雾剂上市申请获受理媒体：长风药业 2026/5/26 公司自主研发的噻托溴铵吸入粉雾剂上市申请已获得NMPA正式受理。作为一种长效（24小时）抗胆碱药，该产品主要用于慢性阻塞性肺病（COPD）的治疗，也可用于慢性支气管炎、肺气肿伴随呼吸困难的维持治疗及急性发作的预防。 4 硕佰医药：获得仁熙基金战略投资，专注呼吸系统吸入创新药研发媒体：药圈时汇 2026/5/22 专注于呼吸系统吸入创新药研发生产企业北京硕佰医药科技有限责任公司获得仁熙基金战略投资。公司核心管线包括：101BHG，为全球唯一具有 M 受体亚型选择性的长效 M 受体拮抗剂，已开发气雾剂、粉吸入剂及鼻喷剂等多种剂型；以及 DBM-1152A，全球唯一进入临床阶段的 MABA 双靶点药物，目前即将进入 III 期临床。 5 浙江仙琚制药股份有限公司关于噻托溴铵奥达特罗吸入喷雾剂药品注册申请获得受理的公告媒体：浙江仙琚制药股份有限公司 2026/5/22 浙江仙琚制药的噻托溴铵奥达特罗吸入喷雾剂被国家药品监督管理局受理，参比制剂为Boehringer Ingelheim的思合华® Spiolto®，用于COPD及其相关呼吸困难的维持治疗。 6 顶峰生物联手上药科园贸易，助力共建中国严重过敏反应急救新生态媒体：顶峰生物医药 2026/5/22 北京顶峰生物与上药科园贸易在北京正式签署战略合作协议，依托各自核心优势共同推动严重过敏急救药物——肾上腺素鼻喷雾剂（优敏速®）的供应链优化与渠道建设，提升药品可及性。合作将将构建“全球创新药+本土龙头流通”，重点补齐院外急救全链路短板。国外头条 International Headlines 1 Texas A&M Researchers Find That Nasal Spray Can Improve Cognitive Function 媒体：sciencedaily 2026/5/26 Researchers at Texas A&M University developed an extracellular vesicle (EV)-based nasal spray that delivers microRNAs directly to the brain, reducing age-related neuroinflammation and improving cognitive function. In preclinical studies, just two doses significantly enhanced memory and cognition, highlighting the potential of a non-invasive therapy for neurodegenerative diseases such as Alzheimer's. 研究发现鼻喷剂可改善认知功能 Texas A&M大学的研究人员开发了一种基于细胞外囊泡（EVs）的鼻喷疗法，可通过鼻腔直接将microRNA递送至脑组织，从而降低与衰老相关的脑部炎症并改善认知功能。动物实验显示，仅两次给药即可改善记忆与认知表现，为阿尔茨海默病等神经退行性疾病治疗提供了新的非侵入性思路。 2 Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution 媒体：Lupin 2026/5/18 Lupin has received tentative approval from the U.S. FDA for its ANDA for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials, which is bioequivalent to Mylan's Yupelri® Inhalation Solution and indicated for the maintenance treatment of patients with COPD. Yupelri® had estimated annual sales of USD 260.7 million in the U.S. Lupin 获得美国 FDA 对 Revefenacin 吸入溶液的暂定批准 Lupin 已获得美国 FDA 对其 Revefenacin 吸入溶液（175 mcg/3 mL 单支装）ANDA 申请的暂时批准。该产品与 Mylan的 Yupelri® 吸入溶液具有生物等效性，适用于慢性阻塞性肺病（COPD）患者的维持治疗。据估算，Yupelri® 在美国的年销售额约为 2.607 亿美元。 3 Quince Acquires OrphAI and Secures Up to $187 Million Financing to Advance Inhaled Pulmonary Disease Pipeline 媒体：Quince Therapeutics 2026/5/18 Quince Therapeutics announced the acquisition of OrphAI Therapeutics, adding LAM-001, an inhaled rapamycin program for rare pulmonary diseases, to its pipeline. Concurrently, the company secured up to $187 million in private financing, providing funding through 2028 to support multiple Phase 2 studies and key clinical milestones. Quince收购OrphAI并完成最高1.87亿美元融资，加速吸入管线布局本次收购包括LAM-001，一种雷帕霉素吸入制剂，用于肺间质病相关肺动脉高压（PH-ILD）和肺移植后闭塞性细支气管炎综合征（BOS）等肺部疾病治疗。与此同时，公司完成最高1.87亿美元私募融资，预计为多项Ⅱ期临床项目提供资金支持，并将现金储备延长至2028年底。 4 SNBL announces new effort to get Satsuma’s Atzumi DHE nasal powder for migraine into the US market 媒体：SNBL 2026/5/11 UCLA researchers developed a broad-spectrum antiviral nasal spray that directly disables viruses before infection. The project showed activity against COVID-19, Ebola and Nipah viruses, and received up to $12.76 million in ARPA-H funding for further development. SNBL宣布推进Atzumi鼻粉剂进入美国市场的新计划 SNBL仍在寻找合作伙伴以推动Satsuma的Atzumi鼻粉剂在美国市场的商业化。目前已与 Trinity Life Sciences 合作推进市场进入。作为首个获批的 DHE 鼻粉剂，该产品采用 SMART技术，用于急性偏头痛治疗。头条速览（2026年5月上） ► 点击阅读头条速览（2026年4月下） ► 点击阅读本公众号致力于分享药物递送领域的前沿信息，促进同行交流与学习。所引用的文章内容均来源于网络，版权归原作者所有。如涉及侵权，请及时联系我们核实处理。本公众号所发布的信息、文章和观点，旨在为读者提供一般性的参考和交流，不构成任何专业建议。本公众号对转载、分享的内容、陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完善性提供任何明示或暗示的保证，仅供读者参考。对于因使用或信赖本公众号信息而引致的任何损失，本公众号概不负责。如需转载，请注明来源于本公众号。

2026-05-29

·米内网

【瞩目】上海医药拿下8亿畅销抗抑郁药

精彩内容 5月29日，上海医药发布公告，其下属山东信谊制药收到国家药监局颁发的《药品补充申请批准通知书》，将盐酸曲唑酮片上市许可持有人由河北龙海药业变更为山东信谊制药。米内网数据显示，盐酸曲唑酮片在2025年中国三大终端六大市场销售额超过8亿元，是抗抑郁化药TOP3产品。药品基本情况盐酸曲唑酮片用于抑郁症的治疗，对伴有或不伴有焦虑的患者均有效。近年中国三大终端六大市场盐酸曲唑酮片销售情况（单位：万元）来源：米内网格局数据库盐酸曲唑酮片在近年中国三大终端六大市场（统计范围见文末）销售规模持续攀升，2025年超过8亿元，同比增长超过30%，是抗抑郁化药TOP3产品，沈阳华泰药物研究的市场份额最大。 2025年中国三大终端六大市场抗抑郁化药TOP5产品来源：米内网格局数据库米内网数据显示，盐酸曲唑酮片有19家企业拥有生产批文，仁合益康集团、重庆海默尼制药、北京福元医药等17家过评，江苏万高药业、合肥英太制药等6家企业以仿制3类报产在审，获批后视同过评。上海医药表示，此次山东信谊制药成为盐酸曲唑酮片的上市许可持有人，进一步丰富公司产品线，有利于提升公司市场竞争力，截至公告日，公司针对该药品已投入约520万元。上海医药今年以来报产在审产品来源：米内网中国申报进度（MED）数据库今年以来，上海医药已有二羟丙茶碱注射液、西格列汀二甲双胍缓释片等3款产品获批上市，瑞维那新吸入溶液、利多卡因丙胺卡因气雾剂等9款产品报产在审，涵盖呼吸系统用药、神经系统药物等多个治疗大类。近期，上海医药捷报频传。5月27日，上药控股与百济神州举行战略合作签约仪式，双方将以资源互补、优势协同为基础，聚焦肿瘤领域创新药商业化，携手构建更高效、更普惠的医药健康服务生态；5月26日，上海医药国际业务事业部（上海医药进出口有限公司）与珠海泰诺麦博制药举行斯泰度塔单抗菲律宾商业化战略合作签约仪式，未来，双方将充分发挥各自在创新药研发、生产质量、注册支持、海外市场准入及本地化商业运营等方面的优势，共同推进斯泰度塔单抗在菲律宾市场的注册申报和商业化落地。资料来源：公司公告、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

100 项与瑞维那新相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10978	瑞维那新	R03BB08	DB11855

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性阻塞性肺疾病	美国	Mylan Ireland Ltd.	2018-11-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸衰竭	临床2期	美国	Mylan Pharmaceuticals, Inc.	2020-11-01
呼吸衰竭	临床2期	美国	Theravance Biopharma, Inc.	2020-11-01
呼吸功能不全	临床2期	美国	Mylan Pharmaceuticals, Inc.	2020-11-01
呼吸功能不全	临床2期	美国	Theravance Biopharma, Inc.	2020-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05165485 (PIFR-2, CTgov)	临床4期	慢性阻塞性肺疾病	404	Revefenacin Placebo+Tiotropium (Tiotropium)	製鬱遞襯夢構壓淵遞襯(餘繭鹽壓鏇衊鑰壓艱積) = 艱願廠廠糧夢衊簾顧憲壓襯鹹窪顧餘襯艱築製 (齋網顧衊廠構醖鬱製簾, 17) 更多	-	2024-12-20
				Tiotropium Placebo+Revefenacin (Revefenacin)	製鬱遞襯夢構壓淵遞襯(餘繭鹽壓鏇衊鑰壓艱積) = 願糧壓襯憲糧鑰蓋鹽鬱壓襯鹹窪顧餘襯艱築製 (齋網顧衊廠構醖鬱製簾, 17) 更多
NCT05046795 (CTgov)	临床3期	慢性阻塞性肺疾病	258	Revefenacin 175 mcg in 3 ML Inhalation Solution (Revefenacin Inhalation Solution 175 mcg QD.)	衊顧築餘糧鏇衊製獵網(鏇獵鑰鹽衊齋廠願膚選) = 構襯窪願遞鹹顧窪蓋憲鬱夢夢襯膚襯蓋壓艱淵 (網構膚窪製觸範鏇蓋築, 23.974) 更多	-	2024-11-01
				Placebo inhalation solution QD (Placebo Inhalation Solution QD.)	衊顧築餘糧鏇衊製獵網(鏇獵鑰鹽衊齋廠願膚選) = 餘製築積衊膚餘壓淵衊鬱夢夢襯膚襯蓋壓艱淵 (網構膚窪製觸範鏇蓋築, 24.504) 更多
NCT02512510 (Pubmed \| Int J Chron Obstruct Pulmon Dis)	临床3期	慢性阻塞性肺疾病	97	Revefenacin 175 μg	壓構齋蓋獵觸觸廠鹽觸(獵範構膚憲醖願顧窪窪) = 鏇顧築鹹窪淵糧衊醖艱簾網糧憲膚襯願膚範壓 (膚鏇襯壓網簾憲醖顧窪 ) 更多	积极	2024-10-01
				Placebo	-
NCT05165485 (PIFR-2, PRNewswire) 人工标引	临床4期	慢性阻塞性肺疾病	404	Revefenacin	夢憲製構夢夢觸築艱選(蓋餘鬱夢膚鬱鹽膚繭觸) = The study did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler. 顧襯選糧夢憲觸糧選選 (窪艱淵選鹹繭蓋憲顧構 ) 未达到	不佳	2024-01-05
				Tiotropium
NCT05046795 (PRNewswire) 人工标引	临床3期	慢性阻塞性肺疾病	257	YUPELRI	選膚願觸壓築衊糧糧製(壓壓鏇膚艱積艱鏇鏇築): Difference = 150.9 (95% CI, 104.1 ~ 197.7) 更多	积极	2023-11-13
				placebo
ATS2021	N/A	严重慢性阻塞性肺疾病	-	Revefenacin 175 µg	願壓衊鬱積蓋鏇願製鹹(蓋淵夢獵鑰觸鏇艱獵構) = 窪廠膚淵鹹餘鑰夢淵鏇觸選憲淵觸蓋艱憲窪鬱 (襯憲遞窪築積淵窪鏇蓋, 85.7 ~ 178.0)	-	2021-05-03
NCT03573817 (Pubmed \| Chronic Obstr Pulm Dis) 人工标引	临床3期	慢性阻塞性肺疾病	122	formoterol+revenacin	淵餘糧選鹽夢製廠壓齋(鏇糧願膚築鹽構鹽衊壓) = 淵鹽蓋遞蓋齋齋遞積鹹範齋壓選蓋餘鏇糧選糧 (鏇膚網願範廠蓋廠鏇憲 ) 更多	积极	2020-04-01
				formoterol+Placebo	淵餘糧選鹽夢製廠壓齋(鏇糧願膚築鹽構鹽衊壓) = 鹹構廠繭膚壓鹽壓衊廠範齋壓選蓋餘鏇糧選糧 (鏇膚網願範廠蓋廠鏇憲 ) 更多
NCT03573817 (CTgov)	临床3期	慢性阻塞性肺疾病	122	Revefenacin+Formoterol (Period 1: Revefenacin + Formoterol (Sequential))	積構膚遞醖選醖醖製鏇 = 鏇衊壓構網製鹹廠獵顧廠壓遞網簾鏇鬱鏇鏇構 (糧餘鬱積衊廠顧鏇繭構, 顧獵繭網簾衊鏇構鬱壓 ~ 構蓋積齋遞鹹壓鹽遞齋) 更多	-	2019-12-18
				Revefenacin+Formoterol (Period 2: Revefenacin + Formoterol (Combo Solution))	積構膚遞醖選醖醖製鏇 = 遞顧簾鏇簾衊築網觸鹹廠壓遞網簾鏇鬱鏇鏇構 (糧餘鬱積衊廠顧鏇繭構, 艱壓鹹憲衊蓋觸淵壓鹽 ~ 鏇餘遞窪選鑰窪餘積築) 更多
NCT02518139 (Pubmed \| Respir Res)	临床3期	慢性阻塞性肺疾病	1,055	Revefenacin 175 μg	膚築淵齋顧選鹹繭餘窪(襯築憲壓鏇齋範窪構膚) = 選遞醖構鑰夢衊艱構築憲鑰餘糧壓艱觸膚鹽糧 (製選鹽糧夢糧淵網觸艱 )	积极	2019-12-01
				Tiotropium	膚築淵齋顧選鹹繭餘窪(襯築憲壓鏇齋範窪構膚) = 積積衊壓遞醖鏇顧糧鹹憲鑰餘糧壓艱觸膚鹽糧 (製選鹽糧夢糧淵網觸艱 )
NCT03064113 (CTgov)	临床2期	慢性阻塞性肺疾病	32	placebo (Placebo)	夢築範築鹽糧淵鬱鏇積(積製遞範繭淵顧衊構醖) = 網觸齋獵簾夢獵網蓋構鏇糧鹽鹽築淵憲築壓選 (獵憲窪膚鏇鬱糧製淵鏇, 32.7) 更多	-	2019-11-14
				TD-4208 (TD-4208 700 μg)	夢築範築鹽糧淵鬱鏇積(積製遞範繭淵顧衊構醖) = 網衊鑰鏇蓋夢鑰鏇選廠鏇糧鹽鹽築淵憲築壓選 (獵憲窪膚鏇鬱糧製淵鏇, 32.7) 更多